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We report isolation of Francisella novicida–causing 
bacteremia in a woman from Thailand who was receiving 
chemotherapy for ovarian cancer. The organism was iso-
lated from blood cultures and identiﬁ  ed by 16S rDNA and 
PPIase gene analyses. Diagnosis and treatment were de-
layed due to unawareness of the disease in this region.  
F
rancisella novicida, a rare human pathogen, has recent-
ly been considered to be a subspecies of F. tularensis 
on the basis of DNA similarity (1,2). The reservoir and 
transmission route of F. novicida were not clearly deﬁ  ned. 
Since the ﬁ  rst isolation of F. novicida, to our knowledge, 
only 5 patients with suspected infection have been reported 
(3–5).  F. novicida, however, has neither been isolated nor 
associated with human disease in Thailand. We report a 
case of F. novicida infection in a Thai patient who was un-
dergoing chemotherapy.
The Study
In October 2007, a 37-year-old woman from Thailand 
sought treatment at Siriraj Hospital (a 2,400-bed university 
hospital in Bangkok, Thailand) with a history of fever for 1 
week. She was a hairdresser residing in a suburban area of 
Prachuap Khiri Khan, a southern province of Thailand. She 
denied history of blood transfusion, animal contact, and 
travel abroad. She had not been aware of being bitten by 
insects recently. There was no incidence of unusual animal 
death in the area in which she resided. Five months before 
seeking treatment, she received a diagnosis of advanced 
stage clear cell adenocarcinoma of the ovary with metas-
tasis to peritoneum, spleen, uterus, and multiple abdominal 
lymph nodes. Chemotherapy was planned. Initial labora-
tory screening showed increased liver enzyme levels and 
abnormal hepatitis markers conﬁ  rming chronic active hep-
atitis B virus infection. Chemotherapy was delayed while 
she was treated with lamivudine. A follow-up visit in early 
September showed that her liver function biochemistry re-
sults had returned to within normal limits. Chemotherapy 
with carboplastin and paclitaxel was then initiated.
At the time of admission, 25 days after the start of 
chemotherapy, the patient had fever (39oC), blood pressure 
90/60 mm Hg, and pulse rate 75 beats/min. She also had 
an episode of gastrointestinal hemorrhage with melena. It 
was believed that fever and gastrointestinal bleeding were 
complications from chemotherapy; thus, microbiologic 
investigation was not promptly initiated. Abnormal labo-
ratory ﬁ  ndings included anemia (hemoglobin 80 g/L) and 
leukocytosis with marked neutrophilia (Figure). Urine and 
stool cultures showed insigniﬁ  cant growth.
Two samples of blood cultures from peripheral lines 
were obtained using BacT/Alert FA bottles (bioMérieux, 
Durham, NC, USA) on day 10 of hospital admission and 
incubated in the continuous monitoring BacT/Alert 3D sys-
tem (bioMérieux). Both blood culture bottles grew small 
pleomorphic gram-negative coccobacillus after incubation 
for 2 days. Samples from positive bottles were subcultured 
onto 5% (vol/vol) sheep blood agar, MacConkey agar, and 
chocolate agar. A slow-growing bacterium was recovered 
on both blood agar and chocolate agar after 2-day incuba-
tion at 35oC with 5% CO2. The organism was negative for 
catalase and oxidase. Bacterial identiﬁ  cation was delayed 
because the organism was unidentiﬁ  able based on the con-
ventional biochemical keys and the Vitek 2 system (bio-
Mérieux, Marcy L’Etoile, France). Using the API 20NE 
(bioMérieux), the organism was identiﬁ  ed as Mannheimia 
haemolytica/Pasteurella trehalosi with good conﬁ  dence 
level (94.5% probability).
The identiﬁ  cation of this isolate was further determined 
by the 16S rDNA gene analysis that used screening prim-
ers SQE1 and SQE3 (6) and the 1,445-bp gene sequencing 
procedure as described elsewhere (7). The DNA sequence 
was analyzed by using the standard nucleotide-nucleotide 
BLAST algorithm (www.ncbi.nlm.nih.gov). The 16S 
rDNA sequence of this isolate, called strain RB401, was 
most closely related (99.9% homology) to the novicida-like 
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Figure. Course of illness in a Thai patient with Francisella novicida 
bacteremia. Solid line, leukocyte count with percentage of 
neutrophils; dashed line, temperature.subspecies of F. novicida strain 3523 (GenBank accession 
no. AY243028) and was deposited to the GenBank data-
base under the accession no. EU365864.
Identiﬁ  cation of strain RB401 was further conﬁ  rmed 
by analyzing DNA sequences of TUL4 and PPIase genes as 
previously described for strain 3523 (5). The fragment con-
taining TUL4 amplicon (363 nt) from strain RB401 shared 
the highest similarity (98%) to the matching region from 
strain 3523. Comparing the 267-nt coding region sequence 
of the 3′ end of PPIase gene nt 733259–733525 to the ge-
nome sequence of F. novicida strain U112 (GenBank ac-
cession no. CP000439) showed the highest similarity to all 
subspecies of F. tularensis, e.g., F. tularensis subsp. tularen-
sis strain WY96-3418 (GenBank accession no. CP000608), 
and to F. novicida strain U112. The PPIase gene sequence 
of strain 3523 was not available for the alignment. Howev-
er, the above ﬁ  ndings also supported that our isolate was F. 
novicida. The sequences of TUL4 and PPIase genes from 
strain RB401 were deposited to GenBank under accession 
nos. EU786119 and EU786120, respectively.
Antimicrobial drug susceptibility testing was per-
formed by disk diffusion method and interpreted based on 
the CLSI criteria for Acinetobacter spp. (8). Results showed 
that strain RB401 was susceptible to piperacillin/tazobac-
tam, third-generation cephalosporins, cefepime, imipenem, 
meropenem, aminoglycosides, ﬂ  uoroquinolones, and tetra-
cycline, but resistant to co-trimoxazole. Due to the delay in 
organism identiﬁ  cation and lack of awareness of its signiﬁ  -
cance, antimicrobial treatment (piperacillin/tazobactam 4.5 
g intravenously every 8 h) was not initiated until day 19. 
However, on day 21, the patient requested to be referred 
to her hometown hospital and died 2 days after referral. 
The ﬁ  nal microbiology report was released 2 days after her 
death. The serologic test for antibodies against Francisella 
spp. was not available. All laboratory technicians who pro-
cessed culture and identiﬁ  ed the bacterium received doxy-
cycline (100 mg twice a day for 14 days) for prophylaxis, 
and none reported fever or abnormal symptoms.
Conclusions
F. novicida, often referred to as F. tularensis subsp. 
novicida, is rarely attributed to human infection and is 
not readily recognized in most clinical laboratories. Be-
cause of the unreliable results of phenotypic identiﬁ  cation 
methods, unfamiliarity of the bacterium and close genetic 
relatedness among Francisella spp., the organism can be 
misidentiﬁ  ed, thus leading to inappropriate management. 
A clinical diagnosis of Francisella infection is highly non-
speciﬁ  c, and it seems that the underlying disease with im-
munosuppression was an important factor to contracting 
the disease in the described case and previous case reports 
(3–5). Human F. novicida infection has not previously 
been described from Asia.
There is no clear explanation regarding route of ac-
quisition and the pathogenic role of this organism. Addi-
tionally, there is no evidence for human-to-human trans-
mission. In our case, clinicians and microbiologists did not 
suspect F. novicida infection. Given that our patient had 
severe complicated underlying diseases while the poten-
tially low-virulence organism was recovered, it was thus 
difﬁ  cult to claim that the patient’s death was solely due to 
F. novicida infection. Notably, the 16S rDNA, TUL4, and 
PPIase sequences of our isolate are most closely related to 
the strain earlier reported from Australia (5). These areas 
are not known to be endemic for F. novicida, and therefore, 
these strains represent the emergence of F. novicida in the 
Asia-Paciﬁ  c region. The earlier case-patient was success-
fully treated with ﬂ  ucloxacillin and doxycycline, followed 
by dicloxacillin and doxycycline (5).
F. novicida is not considered to have a fastidious 
growth requirement. The standard protocol of 5-day incu-
bation for automated blood culture (9) is supposedly suf-
ﬁ  cient for detection of F. novicida bacteremia. Identiﬁ  ca-
tion of F. novicida, however, is often difﬁ  cult because the 
bacterium can be easily misidentiﬁ  ed as a non-Francisella 
species or as a highly pathogenic F. tularensis. It was also 
indicated that this organism could not be detected by a di-
rect ﬂ  uorescent antibody test used for the identiﬁ  cation of 
F. tularensis types A and B (5). As a preliminary result, our 
16S rDNA sequence was closely related to subspecies of F. 
tularensis, and thus doxycycline prophylaxis for the organ-
ism-exposed laboratory personnel could not be avoided. 
There is high risk for laboratory-acquired tularemia when 
handling F. tularensis cultures (10).
In retrospect, prophylactic treatment may have been 
unnecessary because our isolate proved to be F. novicida, 
which is not known to cause laboratory-acquired infec-
tions. Rapid methods for Francisella species identiﬁ  ca-
tion are needed for better consideration of antimicrobial 
prophylaxis. Most F. tularensis strains were susceptible 
to aminoglycosides, quinolones, and tetracyclines (11). 
Our isolate was similarly susceptible to these agents, 
which suggests that they may be considered as therapeu-
tic options for Francisella spp. Initial treatment with pip-
eracillin/tazobactam was based on the preliminary report 
of gram-negative bacilli, but later antimicrobial suscepti-
bility testing showed this isolate to be susceptible to this 
agent. However, previous reports (11–13) suggested that 
piperacillin/tazobactam and other β-lactams are generally 
considered ineffective in vivo against Francisella spp. 
and likely result in therapeutic failure. Given that the or-
ganism is believed to be of low virulence, particularly that 
it does not pose a substantial risk for immunocompetent 
persons, its role as a human pathogen remains controver-
sial. Further studies to gain better understanding of patho-
genic mechanism and transmission route of F. novicida 
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are necessary to provide appropriate guidelines for the 
treatment and prophylaxis. 
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